AU-007
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AU-007, covering 2026-03-31 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer [Phase 1, Phase 2]